Drug Discovery World

JANUARY 3, 2023

AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from RQ Bio in May 2022. . The post Accelerated development for Covid-19 monoclonal antibody appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Immune Response Clinical Trials 52

pharmaphorum

APRIL 14, 2022

Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. The post AbbVie preps filings for lymphoma bispecific licensed from Genmab appeared first on. billion product at peak.

Licensing 62

Licensing Licensing Immune Response Antibody 62

XTalks

APRIL 18, 2022

Top COVID-19 mRNA vaccine maker BioNTech is setting out to explore new and improved delivery technologies for mRNA vaccines, recently announcing a collaboration with New Jersey-based lipid nanocrystal developer Matinas BioPharma. Under the deal, BioNTech will give Matinas BioPharma an upfront exclusive access fee and research funding.

Vaccination 105

Vaccination Vaccine Development Immune Response 105

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 64

Development Research Drugs Antibody 64

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Immune Response 52

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. is biotechnology company focused on developing radiopharmaceutical imaging and therapy agents.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics will make parts of its technology iTANK available to a medical oncologist and researcher at the undisclosed US cancer centre, whose investigation focuses on the development of novel immunotherapies. The iTANK technology platform has been developed for arming and enhancing CAR T-cells for the treatment of solid tumours.

Immune Response 52

Immune Response Gene Therapy Licensing Licensing 52

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. developed dementia over the subsequent two years (vs. Notably, among over-65s who had had Covid-19, 4.5%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

APRIL 8, 2022

billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. Once within the tumour, it stimulates receptors on immune cells to mount an attack on the cancer. It was shown to activate cell-killing immune responses via natural killer (NK) and CD8+ cells, as well as antigen-presenting cells.

Drugs 103

Drugs Immune Response Licensing Licensing 103

XTalks

FEBRUARY 19, 2024

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. Paduano Professor in Pediatrics at Weill Cornell Medicine, in a news release.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

OCTOBER 21, 2022

Swiss pharma giant Roche has moved to strengthen its position in the KRAS-mutated cancer space through a $25 million licensing and collaboration agreement with Austrian arenaviral technology firm Hookipa Pharma. Roche also has the option to license a second, undisclosed, novel arenaviral immunotherapy.

Licensing 52

Licensing Licensing Immune Response Engineer 52

Drug Discovery World

JULY 26, 2023

The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether an IgE antibody could be used to treat cancer. The drug, MOv18 IgE, was developed by researchers at King’s College London. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. . less than one year. Camaisa. .

Trials 52

Trials Immune Response Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Engineer Development Licensing 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Licensing 52

Licensing Licensing Vaccination Vaccine 52

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

SEPTEMBER 23, 2021

Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.

RNA 52

RNA Immune Response Vaccination Vaccine 52

The Pharma Data

APRIL 8, 2022

The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure. a Wyss Technology Development Fellow at the Institute. During his Ph.D.

Immune Response 52

Immune Response In-Vivo Genetic Analysis Research 52

pharmaphorum

DECEMBER 6, 2022

Moderna claims that Comirnaty infringes its patents covering a chemical modification to prevent an unwanted immune response in patients and allow larger doses to be delivered, as well as a proprietary lipid nanoparticle formulation. The post Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit appeared first on.

Vaccination 97

Vaccination Vaccine Immune Response Sales 97

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Our ambition is to develop life-changing treatments for patients.

Immune Response 52

Immune Response Licensing Licensing Sales 52

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases. BMS seems to be interested mainly in AVID200’s potential in cancer, however, at least initially.

Immune Response 57

Immune Response Antibody Drugs Licensing 57

The Pharma Data

JANUARY 12, 2021

Biond Biologics announced today that it has entered into a potentially $1 billion global licensing agreement with Sanofi to take a joint stab at defeating advanced forms of cancer with a more comprehensive and expedited approach to immuno-oncology. . It is being developed for the treatment of solid tumors.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Development 52

pharmaphorum

NOVEMBER 2, 2022

CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. While the exact causes of ALS are not fully understood, research suggests that the mutation of SOD1 may be linked to the development of the condition. What is SOD1 -ALS?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccination 109

Vaccination Vaccine Immune Response Trials 109

pharmaphorum

AUGUST 26, 2022

Among the claims is that Comirnaty was developed using a chemical modification to prevent causing an unwanted immune response in patients which was discovered by Moderna scientists, and that the use of a lipid nanoparticle formulation also infringes its intellectual property. Lawsuits sprouting like mushrooms.

Vaccination 57

Vaccination Vaccine Sales Immune Response 57

pharmaphorum

NOVEMBER 24, 2020

The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Russia approved Sputnik V in August, making it the first coronavirus vaccine worldwide to be licensed worldwide.

Vaccination 109

Vaccination Vaccine Immune Response Marketing 109

pharmaphorum

JANUARY 4, 2023

The hypothesis is that it will induce immune tolerance by stimulating anti-inflammatory regulatory T- (Treg) cells and cytokines that dampen down the immune response. Gilead is collaborating with EVOQ on preclinical-stage projects, and has taken an option to exclusively license rights if they live up to their early promise.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

XTalks

DECEMBER 20, 2021

It has also applied for regulatory licensing in the UK, European Union (EU), Australia, Singapore, India, United Arab Emirates (UAE), New Zealand and Japan. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

pharmaphorum

FEBRUARY 8, 2022

The initial assessment of AT845 is based on four patients who received two doses of the gene therapy, with no evidence of serious adverse events, according to Astellas’ head of clinical development for gene therapies Weston Miller. Shares in the drugmaker rose just over 1% after the FORTIS data was announced.

Gene Therapy 52

Gene Therapy Gene Immune Response Licensing 52

XTalks

AUGUST 13, 2020

In a press statement , Kaiser Permanente outlined that in this phase of the trial, data will be collected about the safety, immune response and efficacy of the vaccine candidate as required for regulatory review.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

The Pharma Data

OCTOBER 6, 2021

It is also licensed under the brand name Efluelda ® in Europe where it is indicated for adults aged 60 and older. The study assesses the safety profile and immune response when COVID-19 mRNA investigational booster vaccine (100 mcg dose) and high-dose quadrivalent influenza vaccine are administered simultaneously.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52